CCL2 and lung cancer: The PDPN-high group revealed significant upregulation of IL-1A, IL-1B, IL-6, IL-10, CCL2, FGF2, PDGFA, PDGFB, and TGF-β1, which contributed to establishing an immunosuppressive microenvironment in patients with lung cancer.